Geron (GERN) to Release Earnings on Monday

Share on StockTwits

Geron (NASDAQ:GERN) is scheduled to announce its earnings results after the market closes on Monday, May 10th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Geron (NASDAQ:GERN) last issued its earnings results on Wednesday, March 10th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.01). Geron had a negative return on equity of 43.76% and a negative net margin of 21,631.02%. The company had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.08 million. During the same quarter in the prior year, the company earned ($0.15) earnings per share. On average, analysts expect Geron to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GERN traded down $0.04 during trading on Tuesday, hitting $1.39. The stock had a trading volume of 24,258 shares, compared to its average volume of 3,408,519. The company has a market capitalization of $442.76 million, a PE ratio of -4.09 and a beta of 1.50. Geron has a twelve month low of $1.15 and a twelve month high of $2.40. The company has a debt-to-equity ratio of 0.10, a quick ratio of 9.60 and a current ratio of 9.60. The stock has a 50 day simple moving average of $1.56 and a two-hundred day simple moving average of $1.74.

Several brokerages have weighed in on GERN. Zacks Investment Research downgraded shares of Geron from a “hold” rating to a “sell” rating in a research note on Monday, February 22nd. HC Wainwright restated a “buy” rating on shares of Geron in a research note on Thursday, April 8th. Finally, B. Riley restated a “buy” rating on shares of Geron in a research note on Wednesday, February 17th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Geron presently has a consensus rating of “Buy” and a consensus target price of $3.83.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

Further Reading: Channel Trading

Earnings History for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with's FREE daily email newsletter.